TORONTO, Nov. 20 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that Gamma-Dynacare Medical Laboratories, leading providers of laboratory services, information and products in Canada, will provide blood specimen collection services for ColonSentry(TM), the world's first blood-based test to determine a person's current risk for colorectal cancer, from an expanded number of laboratory patient service centres in the Toronto area.
"We are very pleased to be working with Gamma-Dynacare as it is one of Canada's largest and most respected providers of medical laboratory services. Gamma-Dynacare is committed to bringing the next generation of medical diagnostic tests to Canadians and ColonSentry(TM) will complement their menu of leading-edge offerings," said Gailina Liew, Chief Operating Officer of GeneNews. "The addition of these sites in the Toronto area will provide a far greater number of patients access to our unique test, an important factor as we continue to drive awareness and increase clinical and patient adoption of the ColonSentry(TM) test."
"Colorectal cancer is the second deadliest cancer in Canada, but is highly curable when detected early. The ColonSentry(TM) test represents a new approach to colorectal cancer screening that is more convenient for patients as the test only requires a simple blood sample," said Ron Hoffman, Vice-President, Business Development, Gamma-Dynacare Medical Laboratories. "We look forward to expanding access to the ColonSentry(TM) test in additional locations in south-western Ontario and Quebec over the next few months. We believe the convenience of this test will result in more patients being screened and we are proud to be the first community laboratory in Canada to assist GeneNews in the introduction of ColonSentry(TM)."
"Gamma-Dynacare is current
|SOURCE GeneNews Limited|
Copyright©2008 PR Newswire.
All rights reserved